Gargano, Maria

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 593

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 522

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 161

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Nishino, M., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2014) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 95